BR112017023841A2 - formulação de hidrogel com adesão suave - Google Patents

formulação de hidrogel com adesão suave

Info

Publication number
BR112017023841A2
BR112017023841A2 BR112017023841A BR112017023841A BR112017023841A2 BR 112017023841 A2 BR112017023841 A2 BR 112017023841A2 BR 112017023841 A BR112017023841 A BR 112017023841A BR 112017023841 A BR112017023841 A BR 112017023841A BR 112017023841 A2 BR112017023841 A2 BR 112017023841A2
Authority
BR
Brazil
Prior art keywords
hydrogel formulation
teat
soft adhesion
adhesion hydrogel
soft
Prior art date
Application number
BR112017023841A
Other languages
English (en)
Other versions
BR112017023841B1 (pt
Inventor
Asfaw Bruktawit
A Zook Christopher
René Claude-Raymond
Dominicovich Ugbedah Dominic
Patricia Carney Fiona
T Sweeney Michael
R Quesnell Rebecca
Barbara Kokotoff Sarah
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of BR112017023841A2 publication Critical patent/BR112017023841A2/pt
Publication of BR112017023841B1 publication Critical patent/BR112017023841B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L29/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

a presente divulgação refere-se a métodos, composições e dispositivos para os tratamentos relacionados ao tecido mamário em sujeitos, incluindo reduzir a incidência de mastite. em particular, a divulgação pode relacionar-se com a criação de uma barreira física em uma superfície da teta, em um canal da teta ou em uma cisterna da teta para o tratamento profilático de transtornos mamários.
BR112017023841-1A 2015-05-06 2016-05-05 Uso de uma composição de hidrogel para tratar ou prevenir mastite no tecido mamário do animal BR112017023841B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562157627P 2015-05-06 2015-05-06
US62/157,627 2015-05-06
PCT/US2016/030961 WO2016179379A1 (en) 2015-05-06 2016-05-05 Hydrogel formulation with mild adhesion

Publications (2)

Publication Number Publication Date
BR112017023841A2 true BR112017023841A2 (pt) 2018-07-31
BR112017023841B1 BR112017023841B1 (pt) 2023-04-18

Family

ID=56027205

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017023841-1A BR112017023841B1 (pt) 2015-05-06 2016-05-05 Uso de uma composição de hidrogel para tratar ou prevenir mastite no tecido mamário do animal

Country Status (14)

Country Link
US (2) US9987362B2 (pt)
EP (1) EP3291820B1 (pt)
CN (1) CN107530277A (pt)
AR (1) AR104541A1 (pt)
AU (1) AU2016256858B2 (pt)
BR (1) BR112017023841B1 (pt)
CA (2) CA3077942C (pt)
CL (1) CL2017002801A1 (pt)
ES (1) ES2949838T3 (pt)
MX (1) MX370083B (pt)
PL (1) PL3291820T3 (pt)
RU (1) RU2693041C2 (pt)
UY (1) UY36676A (pt)
WO (1) WO2016179379A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018213433A1 (en) * 2017-05-16 2018-11-22 Biocure, Inc. Hydrogel medical adhesives
EP3700465A4 (en) * 2017-10-23 2021-08-18 Endologix LLC ENDOLUMINAL AND POLYMER DEVICE

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4113854A (en) 1977-01-10 1978-09-12 Minnesota Mining And Manufacturing Company Prophylactic treatment of mastitis
US4434181A (en) * 1981-12-07 1984-02-28 Fearing Manufacturing Co., Inc. Teat dip
US5017369A (en) * 1987-03-03 1991-05-21 Marhevka Virginia C Film-forming teat sealer for prevention of mastitis and use thereof
DE3934743A1 (de) 1989-10-18 1991-04-25 Eckold Vorrichtung Verfahren zum verbinden zweier bauteile
TW272976B (pt) 1993-08-06 1996-03-21 Ciba Geigy Ag
US5665840A (en) 1994-11-18 1997-09-09 Novartis Corporation Polymeric networks from water-soluble prepolymers
DE69629010T2 (de) 1995-01-16 2004-04-15 Baxter International Inc., Deerfield Selbsttragende flächengebilde aus vernetztem fibrin zur hemmung von postoperativen adhäsionen
TW349967B (en) 1995-02-03 1999-01-11 Novartis Ag Process for producing contact lenses and a cross-linkable polyvinylalcohol used therefor
US5849841A (en) 1995-02-03 1998-12-15 Ciba Vision Corporation Crosslinked polymers containing ester or amide groups
AU4438696A (en) 1995-02-03 1996-08-21 Novartis Ag Crosslinked polymers
TW360671B (en) 1995-02-03 1999-06-11 Novartis Ag Process for producing mold body and the cross-linkable polymer used therein
EP0807269B1 (en) 1995-02-03 1999-10-20 Novartis AG Crosslinkable polymers containing photoinitiators
ATE336307T1 (de) 1995-12-08 2006-09-15 Novartis Pharma Gmbh Plasmainduzierte polymere beschichtungen
US6074657A (en) * 1997-03-20 2000-06-13 Pharmacia & Upjohn Company Administration of an injectable antibiotic in the ear of an animal
US5819988A (en) 1997-04-01 1998-10-13 Sawhney; Ravi K. Double-barreled syringe with detachable locking mixing tip
US6395289B1 (en) * 1998-06-29 2002-05-28 Hydromer, Inc. Hydrophilic polymer blends used to prevent cow skin infections
CA2345018A1 (en) * 1998-09-21 2000-03-30 21St Century Medicine, Inc. Polyvinyl alcohol compounds for inhibition of ice growth
US6652883B2 (en) 2000-03-13 2003-11-25 Biocure, Inc. Tissue bulking and coating compositions
ES2253360T3 (es) * 2000-03-13 2006-06-01 Biocure, Inc. Articulos biomedicos a base de hidrogel.
AU4566001A (en) 2000-03-13 2001-09-24 Biocure Inc Embolic compositions
US20020122771A1 (en) 2000-09-23 2002-09-05 Troy Holland Spray hydrogel wound dressings
AU2002334349B2 (en) 2001-09-10 2008-05-15 Bimeda Research & Development Limited A bio-security system
EP1460982A4 (en) 2001-11-16 2010-04-14 Biocure Inc METHODS FOR INITIATING IN SITU FORMATION OF HYDROGELS
CA2472188C (en) * 2002-01-18 2011-06-21 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
US20060073216A1 (en) * 2002-12-26 2006-04-06 Solution Biosciences, Inc. Compositions and methods for control of bovine mastitis
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
JP2006521180A (ja) 2003-03-25 2006-09-21 バイオキュア・インコーポレーテッド ヒドロゲル糸による医療装置
EP1718237A1 (en) 2004-02-02 2006-11-08 Bimeda Research And Development Limited A method and device for treating a teat canal of an animal
US20050191270A1 (en) * 2004-02-27 2005-09-01 Hydromer, Inc. Anti-infectious hydrogel compositions
US7235592B2 (en) * 2004-10-12 2007-06-26 Zimmer Gmbh PVA hydrogel
US20070249712A1 (en) * 2005-02-04 2007-10-25 Dee Alejandro O Peracetic teat dip
CN101287454B (zh) * 2005-10-12 2011-07-20 兴和株式会社 乳腺癌和/或乳腺炎治疗用离子电渗疗法制剂
WO2007050744A2 (en) 2005-10-26 2007-05-03 Biocure, Inc. Hydrogel spinal disc implants with swellable articles
WO2008153966A1 (en) 2007-06-11 2008-12-18 Biocure, Inc. Mucoadhesive vesicles for drug delivery
EP2227212A1 (en) 2007-12-07 2010-09-15 BioCure, Inc. Bone substitute
US20090253650A1 (en) * 2008-04-03 2009-10-08 Pongsamart S Teat antiseptic prepared from polysaccharide gel with bactericidal and immuno-stimulating activity isolated from durian fruit-rind
EP2332587A1 (de) * 2009-12-12 2011-06-15 Bayer MaterialScience AG Polyurethan-Dispersionen zur Versiegelung von Zitzen der Milchdrüse bei milchliefernden Tieren
US9232805B2 (en) * 2010-06-29 2016-01-12 Biocure, Inc. In-situ forming hydrogel wound dressings containing antimicrobial agents
CA2840061A1 (en) 2011-05-27 2012-12-06 Zurex PharmAgra, Inc. Method of treating a mammalian teat and related compositions
GB201113606D0 (en) 2011-08-05 2011-09-21 Norbrook Lab Ltd Dual chamber syringe
RU2521401C1 (ru) * 2012-12-07 2014-06-27 ГНУ Краснодарский научно-исследовательский ветеринарный институт Российская академия сельскохозяйственных наук (Краснодарский НИВИ) Средство для профилактики мастита у дойных коров в сухостойный период
CN103275351A (zh) 2013-05-27 2013-09-04 山东赛克赛斯药业科技有限公司 一种交联剂、交联聚合物及其制备方法与应用
AU2014318264B2 (en) 2013-09-16 2018-10-04 Zoetis Services Llc Assembly for sequentially delivering substances, and associated methods

Also Published As

Publication number Publication date
BR112017023841B1 (pt) 2023-04-18
PL3291820T3 (pl) 2023-08-21
WO2016179379A1 (en) 2016-11-10
US20160324969A1 (en) 2016-11-10
MX2017014131A (es) 2018-03-15
MX370083B (es) 2019-11-29
AU2016256858A1 (en) 2017-11-02
CA2984614C (en) 2020-07-14
AR104541A1 (es) 2017-07-26
RU2693041C2 (ru) 2019-07-01
AU2016256858B2 (en) 2020-10-08
US20180264118A1 (en) 2018-09-20
CA3077942A1 (en) 2016-11-10
CN107530277A (zh) 2018-01-02
US9987362B2 (en) 2018-06-05
EP3291820A1 (en) 2018-03-14
ES2949838T3 (es) 2023-10-03
CA2984614A1 (en) 2016-11-10
UY36676A (es) 2016-12-30
EP3291820B1 (en) 2023-05-24
RU2017136861A (ru) 2019-06-06
US10449255B2 (en) 2019-10-22
CA3077942C (en) 2022-05-10
CL2017002801A1 (es) 2018-05-11
RU2017136861A3 (pt) 2019-06-06

Similar Documents

Publication Publication Date Title
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
BR112018009010A8 (pt) compósitos poliméricos de sol-gel e usos dos mesmos
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
BR112019023059A2 (pt) composições de limpeza melhoradas
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
BR112018074450A2 (pt) composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
BR112017023805A2 (pt) formulações de tpp1 e métodos para o tratamento de doença lcn2
EP3500344A4 (en) METHOD OF DIAGNOSIS AND TREATMENT OF DRY EYE SYNDROME AND COMPOSITIONS FOR TREATMENT OF A HUMAN EYE
BR112017023170A2 (pt) dispositivo de banho medicinal e seu uso
BR112016028439A2 (pt) implante cirúrgico para correção de hallux valgus ou joanete de alfaiate
BR112017019829A2 (pt) antagonista do receptor nk-3, para o tratamento terapêutico ou cosmético de gordura corporal em excesso
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
EP3668474A4 (en) METHODS OF DIAGNOSIS AND TREATMENT OF DRY EYE SYNDROME AND COMPOSITIONS FOR TREATMENT OF A HUMAN EYE
BR112017023841A2 (pt) formulação de hidrogel com adesão suave
EP3668526A4 (en) COMPOSITIONS FOR TREATMENT OF SKIN AND MUCCOAL INFECTIONS
BR112017009577A2 (pt) análogos de pantotenamida
BR112018012033A2 (pt) composição imunogênica e método para detectar infecção por h. pylori em um sujeito
EP3983076A4 (en) HUMAN MILK OLIGOSACCHARIDES AND COMPOSITIONS THEREOF FOR USE IN THE PREVENTION, MANAGEMENT OR TREATMENT OF MIGRAINE-RELATED SYMPTOMS
EP3402524A4 (en) BIOPHOTONIC COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND SOFT TISSUES AFFECTED WITH NON-RESISTANT OR RESISTANT INFECTIONS OR BOTH
IT201700089011A1 (it) Composizione per il trattamento e la prevenzione di disturbi della sfera sessuale maschile.
BR112017028052A2 (pt) peptídeo, método para induzir uma resposta imune em um sujeito e formulação de vacina
PT3684380T (pt) Formulação aquosa para o tratamento tópico das condições da pele
BR112019021344A2 (pt) Método para o tratamento de doença cardíaca em mamíferos
PL412443A1 (pl) Zastosowanie medyczne kwasu kynureninowego i jego soli

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/05/2016, OBSERVADAS AS CONDICOES LEGAIS